SONUS PHARMACEUTICALS, ISIN: US8356921044... - 500 Beiträge pro Seite

[armerstudent]

Was haltet ihr von Sonus, ist jemand investiert!?
Das Kursziel liegt anscheinend bei $ 18 - aber warum!?
Ich lege mir nach Schließung des Gaps bei $ 5 ein paar Aktien zu!

http://www.sonuspharma.com/

http://finance.yahoo.com/q?s=SNUS

http://www.wallstreet-online.de/market/charts/chartpic.php?u…

http://www.wallstreet-online.de/market/charts/chartpic.php?u…

[js200]

09/25/2003 (13:12 ET) BTC: Smith Barney Sees Cont Profit-Taking in Biotechs - Knobias
09/24/2003 (16:20 ET) SNUS: Short Interest UP 35.1% to 249.3K in Sep 2003 - Knobias
09/24/2003 (14:23 ET) Comment: Big Movers From Weak Biotech Industry - Knobias
09/24/2003 (10:16 ET) VOLUME(+): SNUS Volume 5% > 20-adsv, Stock +12.50% - Knobias
09/24/2003 (09:48 ET) 52W HIGH: New 52-Wk High for SNUS @ $5.600 up13.11% - Knobias

JS200

[boerse-bild]

Hier ein Chart von Snus, den es auf wo nicht gibt!

http://ichart.yahoo.com/z?s=SNUS&t=my&q=c&l=on&z=m&a=v&p=s

Den aktuellen Kurs hatte sie das erste Mal im September 1998, momentan bewegt sie sich seit Tagen zwischen $ 4,90 und $ 5 (bei minimalen Umsätzen)!
Ich denke, sie wird demnächst explodieren - noch fehlen die News!
Mein Kursziel: $ 10 bis Jahresende!

[armerstudent]

Profile for:




Sonus Pharmaceuticals Inc
22026 20th Avenue SE
Bothell, WA 98021
Phone: [phone]
Fax: [phone]
Email: [e-mail]
Web Site: http://www.sonuspharma.com/

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology & Drugs
Employees (last reported count): 37


MULTEX ABRIDGED BUSINESS SUMMARY
Sonus Pharmaceuticals, Inc. is a drug reformulation company focused on the optimization of therapeutic drugs to treat cancer and other serious diseases. The Company is developing a number of potential product candidates utilizing its proprietary TOCOSOL drug delivery technology. The development of therapeutic drugs with TOCOSOL may result in products that can be delivered more conveniently, safely and effectively. The Company`s lead cancer product, TOCOSOL Paclitaxel, is a novel formulation of paclitaxel, a widely used anticancer drug. The Company`s second product utilizing the TOCOSOL drug delivery technology is a novel injectable formulation of camptothecin.


MULTEX ABRIDGED FINANCIAL SUMMARY
For the six months ended 6/30/03, revenues remained flat at $25 thousand. Net loss fell 10% to $5.4 million. Lower losses reflect decreased general and administrative expenses and reduced research and development activities, reflecting the completion of a large part of work on cancer therapy product TOCOSOL Paclitaxel last year.

[armerstudent]

DIRECT COMPETITOR COMPARISON

SNUS CTIC NEOL Pvt1 Industry
Market Cap: 86.63M 412.24M 281.46M 199.97M
Employ­ees: 37 286 100 461 170
Rev. Growth (ttm): -99.70% 170.90% 14.30%
Revenue (ttm): 25.00K 16.90M 01 41.43M
Gross Margin (ttm): 97.45% 57.47%
EBITDA (ttm): -11.03M -50.58M -50.47M 533.00K
Oper. Margins (ttm): 6.88%
Net Income (ttm): -11.04M -61.10M -49.36M -20.00M1 -1.01M
EPS (ttm): -0.81 -1.89 -2.63 0.00
PE (ttm): 26.11
PEG (ttm): 1.29
PS (ttm): 3499.73 17.51 3.92

[armerstudent]

Auf der Seite von Yahoo!Finance habe ich folgendes gefunden!




well well
by: wwatt69 10/09/03 04:28 pm
Msg: 2960 of 2965

Just got off the phone with Pam, she sounds very nice.

We have set up a call for tomorrow morning at 9:30, and the CEO will be sitting in as well... Sounds a little over the top to me, but she said something about having worked out their strategy for TOCOSOL w.r.t. regulatory pathway with the FDA - maybe they are making real progress. I`m excited to hear what they have to say and will probably make sure I`m up to snuff on Multidrug Resistance Proteins....

Keep you informed.
Best


conversation
by: wwatt69 10/10/03 01:03 pm
Msg: 2963 of 2965

Hi all

Just got off the phone with Mike, he was pretty helpful and upbeat. Let me see if I can recap here, can`t promise to keep it in order...

First, he said the results coming out of the current trial continue to be very encouraging, he said they will be presenting at a Chemotherapy conference in NYC on Nov. 14th - that should be exciting. TOCOSOL Paclitaxel continues to be effective where other treatments were not, and he also said something to the effect that it was working in tumors that you wouldn`t expect taxol to work on.

I asked specifically how TOCOSOL might block MDR function - he didn`t have a direct answer, because TOCOSOL is, as it turns out, a multi-component formulation, one component of which is an alpha-tocopherol. I suspected this after doing some research last night - tocopherols have been studied as potential cancer chemotherapy, some of them are directly toxic to tumor cells, some of them seem to effect MDRs depending on which variety they are, alphsa, beta, delta... Alpha tocopherol has been described in the literature as a " membrane-stabilizing" agent, which kind of makes sense. It may inhibit the ability of MDR channels to insert into the membrane somehow. They don`t know exactly, and they don`t want to find out because the regulatory agreement they have nailed down with the FDA does not require Sonus to determine the toxicity or function of any of the individual components of TOCOSOL, just the vehicle as a whole. Mike pointed out, however, that in the early trials in melanoma xenografts which were then biopsied and analyzed for drug retention, TOCOSOL Paclitaxel produced 2-fold higher uptake/retention of the drug in tumors compared to Paclitaxel alone. Uptake/retention in all other, normal tissues was exactly the same among the two, which is a strong suggestion that there is something about TOCOSOL function that keeps it in tumor cells specifically, which implicates MDR blockage.

The regulatory route they are taking is 5052b. I do not know this nomenclature, perhaps someone here could edify us, but Mike said that will shorten the route to nda submission/approval by 2 years.

I told him my concerns about increasing blood brain barrier permeability vis-a-vis the Camptothecin application, he reminded me that in all tissues other than tumor, TOCOSOL Paclitaxel had the same absorption as Paclitaxel alone, indicating no increase in permeability. He also said that they are not going balls to the wall with Camptothecin at this point because they don`t want to run out of money.

I think that`s about it - he was quite convincing, and seemed excited about the emerging trial results, and of course said that the next couple of months should be exciting.

If I remember anything else I`ll post. Hope this is helpful, I`m encouraged.
Best...

[armerstudent]

Just listened to this---and as per usual, you pick up a lot more SNUS info in the CCs than in official printed statements.
Mike Martino did a superb presentation job as usual.
In contrast to past statements, he did refer to the IP around Tocosol, stating that they have filed 27 patents, and their patent assessment of others` claims comes up with a very healthy situation in favor of SNUS.
Mike covered the various clinical trials in the planning and the 505b agreed FDA strategy.
Finally he implied that the partnership discussions are tough---and that SNUS may not be able to conclude an agreement in 2003, but may go into 2004 before they do this; always being driven by value rather than the calendar.
This is the first indication that this important milestone may slip into 2004 (IMO)....something new.